On September 28, 2026, Jefferies initiated coverage of Q32 Bio (NASDAQCM:QTTB) with a “Buy” recommendation. The stock closed at $9.23 on that day, after a pre-action close of $8.77 on September 25, indicating a decline of 11.84% over the past week and 38.59% over the past month.
As of September 15, 2026, the consensus target price for Q32 Bio is $41.82, suggesting a potential upside of 353.09% from current trading levels. The company reported a quarterly EPS of -0.43 on August 5, 2026, compared to an estimated EPS of -0.553.
Analyst sentiment reflects positivity, with 12 total recommendations as of September 1, 2026: 3 strong buy, 8 buy, and 1 hold, yielding a positive recommendation percentage of 91.7%.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
